Top-Rated Dividend StocksTop-Rated DividendNYSE:ABT Abbott Laboratories (ABT) Stock Price, News & Analysis $104.82 +0.11 (+0.11%) As of 11:57 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Abbott Laboratories Stock (NYSE:ABT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abbott Laboratories alerts:Sign Up Key Stats Today's Range$103.26▼$105.9150-Day Range$96.62▼$115.5852-Week Range$81.97▼$131.49Volume1.97 million shsAverage Volume11.04 million shsMarket Capitalization$181.54 billionP/E Ratio39.12Dividend Yield2.40%Price Target$118.32Consensus RatingModerate Buy Company Overview Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States. Founded in 1888 by physician Wallace Calvin Abbott, the company is headquartered in Abbott Park, Illinois, and serves customers around the world. Robert B. Ford is Abbott’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Abbott Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreABT MarketRank™: 4.446808510635 of 5 starsAbbott Laboratories scored higher than 89% of companies evaluated by MarketBeat, and ranked 38th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingAbbott Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 21 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialAbbott Laboratories has a consensus price target of $118.32, representing about 13.8% upside from its current price of $103.99.Amount of Analyst CoverageAbbott Laboratories has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Abbott Laboratories' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth7.25% Earnings GrowthEarnings for Abbott Laboratories are expected to grow by 7.25% in the coming year, from $5.52 to $5.92 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abbott Laboratories is 38.80, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.89.Price to Earnings Ratio vs. SectorThe P/E ratio of Abbott Laboratories is 38.80, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.98.Price to Earnings Growth RatioAbbott Laboratories has a PEG Ratio of 1.88. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAbbott Laboratories has a P/B Ratio of 3.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Abbott Laboratories' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.11% of the float of Abbott Laboratories has been sold short.Short Interest Ratio / Days to CoverAbbott Laboratories has a short interest ratio ("days to cover") of 1.91, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abbott Laboratories has recently increased by 9.61%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAbbott Laboratories pays a meaningful dividend of 2.35%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAbbott Laboratories has been increasing its dividend for 54 years.Dividend CoverageThe dividend payout ratio of Abbott Laboratories is 94.03%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 42.57% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.Read more about Abbott Laboratories' dividend. News and Social Media4.5 / 5News Sentiment1.27 News SentimentAbbott Laboratories has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Abbott Laboratories this week, compared to 10 articles on an average week.Search Interest51 people have searched for ABT on MarketBeat in the last 30 days. This is an increase of 28% compared to the previous 30 days.MarketBeat Follows32 people have added Abbott Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 220% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Abbott Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $408,958.00 in company stock.Percentage Held by Insiders0.46% of the stock of Abbott Laboratories is held by insiders.Percentage Held by Institutions75.18% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abbott Laboratories' insider trading history. Receive ABT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABT Stock News HeadlinesAbbott (ABT) Stock May Be 28% Undervalued Despite AI Testing ExpansionNovember 17 at 5:52 PM | finance.yahoo.comGlobal Point of Care (POC) Immunoassay Analyzer Expansion Market 2026 | Capture 8.8% CAGR to 2030 as Roche, Abbott, Siemens Healthineers and Danaher Scale AI-Enabled POC TestingNovember 16 at 3:11 PM | finance.yahoo.comYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.November 18 at 1:00 AM | Reagan Gold Group (Ad)Non-Animal Alternative Testing - Global Strategic Business Report 2026: Capitalize on 13.3% CAGR and $4.7B by 2032 as Abbott, Charles River, Emulate, Evotec, and Bio-Rad Reshape TestingNovember 16 at 3:11 PM | finance.yahoo.comInsider Selling: Abbott Laboratories (NYSE:ABT) EVP Sells $406,000.00 in StockNovember 7, 2026 | insidertrades.comMarketBeat Week in Review – 10/19 - 10/23 (ABT)A market sell-off spread beyond tech as oil prices surged and AI concerns grew. MarketBeat analysts recap the week's top stories on earnings, from Halliburton to Meta Platforms and General Motors.October 24, 2026 | marketbeat.com3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach (ABT)Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.October 23, 2026 | marketbeat.comCologuard Is Working—So Why Isn’t Abbott Stock?Abbott's stock fell 4% despite solid Q3 results, as it trimmed full-year sales guidance and announced plans to spin off its Nutrition business into a separate public company by 2027.October 22, 2026 | marketbeat.comSee More Headlines ABT Stock Analysis - Frequently Asked Questions How have ABT shares performed this year? Abbott Laboratories' stock was trading at $125.30 at the beginning of 2026. Since then, ABT stock has decreased by 17.0% and is now trading at $103.9880. How were Abbott Laboratories' earnings last quarter? Abbott Laboratories (NYSE:ABT) released its quarterly earnings results on Wednesday, October, 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories's revenue was up 14.5% compared to the same quarter last year. Read the conference call transcript. Does Abbott Laboratories have any subsidiaries? Abbott Laboratories subsidiaries include these companies: Cephea Valve Technologies, Alere, St. Jude Medical, Kalila Medical, Tendyne Holdings Inc., Veropharm, Topera Inc., and others. Who are Abbott Laboratories' major shareholders? Top institutional investors of Abbott Laboratories include State Street Corp (4.70%), Assenagon Asset Management S.A. (0.30%), Barrow Hanley Mewhinney & Strauss LLC (0.29%) and Sumitomo Mitsui Trust Group Inc. (0.21%). Insiders that own company stock include Daniel J Starks, Robert B Ford, Jr Robert E Funck, Jr Robert E Funck, Daniel Gesua Sive Salvadori, Mary K Moreland, Andrea F Wainer, Lisa D Earnhardt, Eric Shroff, Elizabeth C Cushman, John A Jr Mccoy and Philip P Boudreau. View institutional ownership trends. How do I buy shares of Abbott Laboratories? Shares of ABT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abbott Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abbott Laboratories investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Walmart (WMT), JPMorgan Chase & Co. (JPM) and ExxonMobil (XOM). Company Calendar Record date for 11/16 Dividend10/15/2026Ex-Dividend for 11/16 Dividend10/15/2026Last Earnings10/21/2026Dividend Payable11/16/2026Today11/18/2026Fiscal Year End12/31/2026Next Earnings (Estimated)1/28/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, ABT's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:ABT CIK1800 Webwww.abbott.com Phone(224) 667-6100Fax847-937-1511Employees115,000Year Founded1888Price Target and Rating Average Price Target for Abbott Laboratories$118.32 High Price Target$135.00 Low Price Target$92.00 Potential Upside/Downside+13.5%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage28 Analysts Profitability EPS (Trailing Twelve Months)$2.68 Trailing P/E Ratio38.90 Forward P/E Ratio17.60 P/E Growth1.88Net Income$6.52 billion Net Margins9.75% Pretax Margin13.61% Return on Equity18.04% Return on Assets9.09% Debt Debt-to-Equity Ratio0.57 Current Ratio1.45 Quick Ratio1.00 Sales & Book Value Annual Sales$44.33 billion Price / Sales4.07 Cash Flow$6.78 per share Price / Cash Flow15.37 Book Value$29.81 per share Price / Book3.50Miscellaneous Outstanding Shares1,731,940,000Free Float1,723,975,000Market Cap$180.47 billion OptionableOptionable Beta0.54 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:ABT) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersGold Trades Near Record Highs: What It Means for MinersBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...Behind the Markets | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abbott Laboratories Please log in to your account or sign up in order to add this asset to your watchlist. Share Abbott Laboratories With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.